301097SZSE
🚨 Material Event

Announcement on Company's New Product Obtaining Drug Registration Certificate

Tianyi Medical Co., Ltd.··2 pages

✨ AI Summary

Ningbo Tianyi Medical has received a Drug Registration Certificate for its new product, Sodium Citrate Hemofiltration Replacement Fluid. This marks an expansion into higher-value pharmaceutical products, enhancing the company's position in the blood purification market. The company anticipates market entry and sales will depend on future market development.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 301097 Securities Abbreviation: Tianyi Medical Announcement No.: 2026-011

Ningbo Tianyi Medical Device Co., Ltd. Announcement on Company's New Product Obtaining Drug Registration Certificate

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

Ningbo Tianyi Medical Device Co., Ltd. (hereinafter referred to as the "Company") subsidiary, Ningbo Tianyi Pharmaceutical Co., Ltd. (hereinafter referred to as "Tianyi Pharmaceutical"), recently received a Drug Registration Certificate issued by the National Medical Products Administration, the details of which are as follows:

I. Details of the Drug Registration Certificate

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.